Genmab | GEN - Cost Of Sales


Genmab reported DKK84M in Cost of Sales for its fiscal quarter ending in June of 2026.





Cost Of Sales Change Date
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
Almirall EUR 199.26M 7.76M Jun/2026
Amarin USD 26.05M 1.41M Dec/2025
Amgen USD 1.87B 271M Jun/2026
argenx SE USD 145M 24M Jun/2026
AstraZeneca USD 2.52B 2.73B Jun/2026
Bayer EUR 4.54B 692M Jun/2026
BioMarin Pharmaceutical USD 276.29M 76.8M Jun/2026
Demant DKK 2.89B 188M Dec/2025
Exelixis USD 20.66M 704K Jun/2026
Fresenius Medical Care EUR 3.55B 117.58M Jun/2026
Genmab DKK 84M 19M Jun/2026
GlaxoSmithKline GBP 2.07B 192M Jun/2026
GN Store Nord DKK 1.16B 1.08B Mar/2026
GRIFOLS EUR 1.17B 90M Jun/2026
Hikma Pharmaceutical USD 959M 492.5M Dec/2025
Insmed USD 69.29M 19.79M Jun/2026
Lakefront Biotherapeutics EUR 4.8M 4.34M Mar/2026
Lonza CHF 2.28B 189M Jun/2025
Merck EUR 2.27B 199M Jun/2026
Novartis USD 3.71B 251M Jun/2026
Regeneron Pharmaceuticals USD 576.5M 92.9M Jun/2026
Roche Holding CHF 7.85B 630M Jun/2026
Sanofi EUR 3.02B 656M Jun/2026
UCB EUR 1.07B 146M Dec/2025